Recombinant Human VSIG10L Fc Chimera Protein, CF

Recombinant Human VSIG10L Fc Chimera (Catalog # 9600‑VS)inhibits IFN‑ gamma secretion by human peripheral blood mononuclear cells in thepresence of anti-CD3 antibody. The ED50 for this effect is 1-6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSIG10L Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human VSIG10L protein
  

  Human VSIG10L (Leu28-Ala776) Accession # Q86VR7-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q86VR7-1
• N-terminal Sequence: Leu28 and Ser176
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 106 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 120-140 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSIG10L Fc Chimera Protein, CF

• V-Set And Immunoglobulin Domain Containing 10 Like
• V-Set And Immunoglobulin Domain-Containing Protein 10-Like
• VSIG10L

Background

V-set and immunoglobulin domain-containing protein 10-like (VSIG-10L) is an 840 amino acid (aa) single-pass type I membrane protein of the Ig superfamily. The protein consists of a 749 aa extracellular domain (ECD), a 21 aa helical transmembrane domain, and a 70 aa cytoplasmic domain. The ECD of VSIG-10L contains both an Ig-like C2-type 1 domain and an Ig-like C2-type 2 domain. The ECD of mature human VSIG-10L shares 95%, 75%, and 74% identity with Rhesus macaque, mouse, and rat, respectively. The specific biological function of VSIG-10L has yet to be elucidated, but there is evidence to suggest the molecule is involved in cell‑cell adhesion. Ig-like C2-type domains are similar to antibody constant domains and can be found in T cell adhesion molecules, such as Cluster of Differentiation 2 (CD2) along with vascular and intercellular cell adhesion molecules (VCAM and ICAM, respectively) (1). VSIG-10L is highly expressed in healthy esophagus with squamous mucosa (2). Down‑regulation of the protein may be linked to familial Barrett's esophagus and esophageal adenocarcinoma (2) while up‑regulation may be linked to lung squamous cell carcinoma (3). R&D in house data indicate that VSIG-10L inhibits the secretion of IFN-g from anti-CD3 activated human PBMCs.

1. Yang H and Reinherz E (2001) J. Biol. Chem. 276(22):18775.
2. Fecteau RE, et al. (2016) JAMA Oncol. 2(10):1333.
3. Tian F, et al. (2017) J. Thorac. Dis. 9(1):42.

Bioinformatics

• Uniprot:
  • Q86VR7-1()